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Abstract
Background: Previous studies established that PP1 is a target for Bcl-2 proteins and an important regulator of apoptosis.
The two distinct functional PP1 consensus docking motifs, R/Kx(0,1)V/IxF and FxxR/KxR/K, involved in PP1 binding and cell
death were previously characterized in the BH1 and BH3 domains of some Bcl-2 proteins.
Principal Findings: In this study, we demonstrate that DPT-AIF1, a peptide containing the AIF562–571 sequence located in a
c-terminal domain of AIF, is a new PP1 interacting and cell penetrating molecule. We also showed that DPT-AIF1 provoked
apoptosis in several human cell lines. Furthermore, DPT-APAF1 a bi-partite cell penetrating peptide containing APAF-1122–131,
a non penetrating sequence from APAF-1 protein, linked to our previously described DPT-sh1 peptide shuttle, is also a
PP1-interacting death molecule. Both AIF562–571 and APAF-1122–131 sequences contain a common R/Kx(0,1)V/IxFxxR/KxR/K
motif, shared by several proteins involved in control of cell survival pathways. This motif combines the two distinct PP1c
consensus docking motifs initially identified in some Bcl-2 proteins. Interestingly DPT-AIF2 and DPT-APAF2 that carry a F to A
mutation within this combinatorial motif, no longer exhibited any PP1c binding or apoptotic effects. Moreover the F to A
mutation in DPT-AIF2 also suppressed cell penetration.
Conclusion: These results indicate that the combinatorial PP1c docking motifR/Kx(0,1)V/IxFxxR/KxR/K,deduced from AIF562–571
and APAF-1122–131 sequences, is a new PP1c-dependent Apoptotic Signature. This motif is also a new tool for drug design that
could be used to characterize potential anti-tumour molecules.
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Introduction
The dynamic process of signal transduction, which involves the
concerted action of both protein kinases and protein phospha-
tases, is a major mechanism in the control of a wide variety of
cellular regulations. The PPP family of serine and threonine
protein phosphatases, which includes PP1, PP2A, PP2B, and PP4
through to PP7, is responsible for intracellular phospho-serine
and phospho-threonine dephosphorylation. The PP1 family of
serine/threonine protein phosphatases has been implicated in the
regulation of many cellular processes including apoptosis in
mammalian cells [1]. PP1 proteins do not exist as free catalytic
subunits in the cell but as oligomeric complexes comprising a
catalytic structure (PP1c), exerting enzymatic activity, asso-
ciated with an interacting subunit [2]. The binding of different
subunits to a catalytic structure generates a broad variety of
holoenzymes.
Apoptosis-inducing factor (AIF) and Apoptotic Protease-Activat-
ing Factor 1 (APAF-1) are two major and distinct effectors of
apoptosis. AIF is an important mitochondrial flavoprotein involved
in the caspase-independent death pathway. Upon cell insults, AIF is
released from the mitochondria and translocates to the nucleus [3].
In contrast, and in response to distinct cell death stimuli, APAF-1
controls caspase activation downstream of the mitochondria [4].
To identify potential PP1-interacting proteins, we previously
proposed a concept of PP1-signature based on the simultaneous
presence of the two distinct PP1c docking motifs, R/Kx (0.1)V/IxF
and FxxR/KxR/K [5]. These motifs which are detectable in most
PP1-interacting proteins, were initially identified in certain anti-
apoptoticmembersoftheBcl-2family[6].Inaddition,wealsomore
recently described a novel approach for rational drug design, called
DPT, which is based on the intracellular delivery of apoptotic PP1/
PP2A interacting peptides. Based on these concepts we demon-
strated that introduction of the PP1c-interacting FxxR/KxR/K
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2 family, triggered cell death in HeLa and Jurkat cells [7].
This study is based on the observation that the human AIF562–571
sequence contains 10 amino-acid residues which combine the two
PP1 consensus docking motifs R/Kx(0.1)V/IxF, and FxxR/KxR/K
identified in certain Bcl-2 proteins. Furthermore, based on
co-precipitation analyses and apoptotic studies, we propose that
the R/K-x(0.1)V/IxFxxR/KxR/K consensus sequence deduced
from AIF562–571 sequences is a new PP1-docking motif that is
sufficient to provoke cell death in human cell lines. These results also
suggest that this combinatorial PP1c docking motif is potentially a
molecular tool for drug design.
Materials and Methods
Cell culture and reagents
Six distinct transformed adherent cell (HeLa, PC3, HCT116
p53+/+, HCT116 p532/2, U-2OS, h-TERT RPE-1) were
obtained from ATCC. (HFF), Human foreskin fibroblasts also
from ATCC was a gift from Dr. MA Buendia (Institut Pasteur).
These cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) as exponentially growing subconfluent
monolayers in microplates or in 12, 24 or 96-well plates. Non
adherent Jurkat lymphoid T cells (clone E6, ATCC) were cultured
in RPMI 1640 glutamax medium (Gibco). All cell lines were
cultured in medium supplemented with 10% (v/v) fetal calf serum.
Peptides
High-performance liquid chromatography-purified NH2–bioti-
nylated peptides (purchased from Neosystem) were prepared by
solid-phase peptide synthesis then dissolved in DMSO and stored
at 220uC pending use.
Antibodies
PP1 antibodies (Monoclonal anti E9) and Anti-mouseIgG-HRP
were obtained from Santa Cruz.
Kits and Reagent
Lab-Tek II Chamber Slide w/Cover, 8 well (Ref 154534, Nalge
Nunc International), streptavidin Horse Radish Peroxidase conju-
gate (Euromedex,), 3,39-diaminobenzydine tetrahydrochloride
(DAB) of DAB substrate Kit for Peroxidase (Vector laboratories),
‘‘complete mini EDTA free’’ protease inhibitor cocktail from Roche,
O-Phenylenediamine dihydrochloride (OPD) tablet from Sigma
chemical, Annexin-V-FITCfrom Roche,DiOC6(3) fromSigma, Kit
DeadEnd
TM Fluorometric TUNEL system product (Promega),
FluorSave
TM Reagent from Calbiochem, Vectashield mounting
medium for fluorescence, with DAPI (Vector Laboratories).
PP1c-binding assays on cellulose-bound APAF peptides
Overlapping dodecapeptides scanning the partial sequence
APAF domain encompassing residues 119–141 with putative
PP1c docking motif, were prepared by automated spot synthesis
(Abimed, Langerfeld, Germany) onto an amino-derived cellulose
membrane, as described [8,9]. Membrane was blocked using
SuperBlock (Pierce), incubated with purified PP1c and after
several washing steps, incubated with anti-PP1c antibody followed
by PO-conjugated secondary antibody. Spots corresponding to
positive peptides were visualized using the ECL system.
Pull down assays to detect interaction of biotinylated
peptides with PP1c
Biotinylated peptides were pre-incubated for 2 h at 100 mM( f i n a l
concentration with lysate) and room temperature with 30 mlo f
streptavidin-coated immunomagnetic beads (Calbiochem, San Diego
CA). During this time, 1610
6 HeLa cells at 90% of confluence per
test peptide were washed with PBS, trypsinized, harvested with PBS,
washed with 1 ml of PBS, and centrifuged at 600 g and 4uCf o r
10 min. Cell pellets were lysed 10 min on ice with 400 mlo fl y s i s
buffer (50 mM Tris pH 7.4, 200 mM NaCl, 10 mM EDTA, 20%
Glycerol, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 10 mM NaF, 1 mM orthovanadate, and ‘‘complete mini
EDTA free’’ protease inhibitor cocktail from Roche). Lysates were
clarified at 13,000 g for 10 min at 4uC and after rotation with
s u p e r n a t a n ta t4 uC for 2 h, biotinylated peptides were pulled down
with streptavidine magnetic beads and washed twice with 750 mlo f
lysis buffer. Bound proteins and clarified lysates were analyzed by
western blotting using PP1 antibodies.
Table 1. Homology of the PP1c consensus binding motifs deduced from the AIF sequence in different species.
SPECIES and PP1 motifs SEQUENCE OF AIF PROTEINS
Human 562–KgViFylRdK–571
Mouse 561–KgViFylRdK–570
Rat 561–KgViFylRdK–570
Chicken 540–KgViFylRdK–550
First PP1c consensus docking motif characterized in Bcl-xL and Bcl–w proteins. (R/K)x(0,1)V/IxF
Second PP1c consensus docking motif characterized in Bcl-xL and Bcl–w proteins. Fxx(R/K)x(R/K)
A new combinatorial Potential motif (R/K)x(0,1)V/IxFxx(R/K)x(R/K)
AIF proteins contain a putative PP1c docking sequence (R/K)x (0,1)V/IxFxx(R/K)x(R/K) which combines the two canonical PP1c docking motifs (R/K)x(0,1)V/IxF and
Fxx(R/K)x(R/K) initially characterized in certain Bcl-2 proteins [1,6].
Sequences are shown with a single letter code for amino acids, and residues corresponding to invariable amino acids in the PP1c site are in capital letters.
doi:10.1371/journal.pone.0009981.t001
Table 2. Origin and sequences of peptides containing human
AIF562–571.
ORIGIN ACRONYM SEQUENCES
AIF562–571 DPT-AIF1 KgViFylRdK
AIF562–571 DPT-AIF2* KgViAylRdK
A single letter amino acids code is used for all peptides, and residues
corresponding to invariable amino acids in PP1c consensus binding sites are in
capital letters. *This peptide contains a single F/A mutation that destroys the
combinatorial PP1c docking motif.
doi:10.1371/journal.pone.0009981.t002
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A total of 4610
4 exponentially proliferating HeLa cells growing
in a subconfluent monolayer were seeded per well on a Lab-Tek II
Chamber Slide w/Cover in an 8-well configuration (Ref 154534,
Nalge Nunc International) and incubated at 37uC, 5% CO2.4 8h
later, biotinylated peptides were added to the cells at different
concentrations and for different periods of time at 37uC, 5% CO2.
Cells were washed twice in PBS, and fixed with absolute ethanol
for 10 min at 220uC before addition of 100 mM of streptavidin
HRP conjugate (Cat # 18-152, Euromedex). After 30 min
incubation at 37uC, cells were rinsed twice in PBS and incubated
with DAB (Vectorshield) for around 10 min. Cells were washed in
distilled water and mounted for microscopic examination.
Quantification of Peptide Internalization
Before incubation, the peptides were preincubated for 1 h with
streptavidin HRP conjugate in a 4/1 ratio. Cells at 80% confluence
were incubated with different concentrations of peptide in 24-well
Figure 1. Co-precipitation of PP1c with DPT-AIF peptides
containing a wild type or single F565/A mutation. PP1c from
HeLa cell extracts associated with biotinylated DPT-peptides containing
AIF562–571 sequences (‘‘bound’’ panel) in pull-down experiments was
identified by immunoblotting with anti-PP1c antibodies. PP1c identi-
fication in lysates (‘‘unbound’’ panel) is shown as a control.
doi:10.1371/journal.pone.0009981.g001
Figure 2. Effect of DPT-AIF peptides on the cell penetration and intracellular delivery of streptavidin-peroxidase. (A) In the penetration
and localization tests, HeLa cells were incubated with 150 mM DPT-AIF peptides for 2 hrs at 37uC, and before any microscopy, the presence of DPT-
AIF peptides was revealed by a colorimetric test DAB. (B) Intracellular delivery of streptavidin-peroxidase by biotinylated- DPT-AIF and TAT peptides in
HeLa cells. Streptavidin-peroxidase coupled with biotinylated peptides incubated for 6 hrs at 37uC with internalized complexes visualized by a
colorimetric test OPD as indicated in Methods. Statistical analysis was by ANOVA test and significance was set at P,0.05.
doi:10.1371/journal.pone.0009981.g002
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(Trypsin EDTA, Invitrogen) and harvested in 1 ml of PBS and
counted. Cells were lysed in 300 ml of 0.1 M Tris pH 7.4, and 0.5%
Nonidet P-40 buffer for 10 min on ice. A total of 50 ml of cell lysate
was mixed with 50 ml of OPD buffer (51.4 mM Na2HPO4 and
24.3 mM citric acid) then mixed with 100 ml of OPD solution (one
OPD tablet from Sigma (St. Louis MO) in 100 ml of OPD buffer to
which 40 ml of 30% hydrogen peroxide was added just before use).
After 10 to 20 min, the reaction was stopped by adding 100 mlo f
1 M HCl, and optical density was read at 490 nm.
Cytotoxicity assays
A total of 3,000 cells were incubated for 24 hours with different
peptide concentrations. Peptide cytotoxicity in adherent cell lines
was analyzed by a colorimetric assay using 3-(4,5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (called MTT) for adherent
cells as described by the manufacturer (Sigma).
TUNEL Assay
TUNEL assays were performed using the DeadEndTM
Fluorometric TUNEL system product (G3250 Promega). A total
of 4610
4 exponentially proliferating HeLa cells growing as a sub
confluent monolayer were seeded per well on a Lab-Tek II
Chamber Slide w/Cover in an 8–well configuration (Ref 154534,
Nalge Nunc International) and incubated at 37uC, 5% CO2.1 8h
later, biotinylated peptides were added to the cells at different
concentrations and for different periods of time at 37uC, 5% CO2.
After incubation, cells were rinsed twice with 1X PBS and were
Figure 3. Effect of DPT-AIF peptides on cell survival and cell death. Cell viability assay: (A) HeLa cells, or (B) other adherent cell lines, were
incubated for 24 hours with DPT-AIF peptides prior to processing for MTT staining. In A, SD is shown for n=3, in B for simplicity the figure
corresponds to a representative experiment repeated three times. Cell death assay: (C) HeLa cells were incubated for 2 hrs with DPT-AIF peptides
prior to processing for the detection of TUNEL positive cells. The % of positive cells was obtained by ANOVA test and significance was set at P,0.05.
(D) To monitor apoptosis in Jurkat cells treated with DPT-AIF peptides, we used Annexin V (left panel) or DiOC6 (right panel) assays as described in
Methods. Statistical analysis was by ANOVA and significance was set at P,0.05.
doi:10.1371/journal.pone.0009981.g003
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4uC. Slides were rinsed twice with 1X PBS for 5 min and
permeabilized with a solution consisting of 0.2% Triton X-100 in
1X PBS for 5 min at room temperature. Cells were washed twice
with 1X PBS prior to labeling. Cells are equilibrated with kit
‘‘Equilibration Buffer’’ for 10 min at RT. TUNEL reaction
labeling was performed by using the specified amounts of the
‘‘Equilibration Buffer’’, ‘‘Nucleotide Mix’’ and ‘‘rTdT Enzyme’’
and incubated for 60 min in the dark at 37uC in a humidified
chamber. To stop the reaction, the slides were immersed for
15 min in 2X SSC (in 1X PBS) purchased from Promega. Slides
were rinsed three times in 1X PBS and mounted with Vectashield
containing DAPI. The slides were examined by fluorescence
microscopy.
Annexin-V assays and evaluation of mitochondrial
membrane potential (DYm)
Jurkat cells (2.4.10
5 cells in 400 ml of complete RPMI-1640
medium) were incubated at 37uC and 5% CO2 with different
peptide concentrations. After 3 h, cells were washed in PBS and
we used an Annexin-V-FITC (Roche) to assess outer leaflet
phosphatidylserine (PS) exposure in the plasma membrane as a
means for the early detection of apoptotic cells. Staining was
performed according to the manufacturer’s instructions. We also
used the cationic Dye DiOC6(3), which localizes into intact
mitochondria, to measure DYm. DiOC6(3) was added at 20 nM
for 15 to 30 min at 37uC in the dark. Cells were washed in PBS
and immediately analyzed by flow cytometry. A total of 20,000
cells were analyzed in a FACScalibur flow cytometer (BD
Biosciences, San Jose, CA).
Results
AIF562-571, a short c-terminal sequence of human AIF, is a
new PP1-interacting sequence
As shown in table 1, the highly conserved c-terminal domain of
AIF proteins contains a putative PP1c docking motif, R/Kx(0.1)V/
IxFxxR/KxR/K, that combines the two previously reported
canonical PP1c docking motifs required for PP1c binding in Bcl-
xL and Bcl-w proteins [6]. To test the binding capacity of this motif
to PP1c, we chemically synthesized DPT-AIF1 and DPT-AIF2, two
biotinylated peptides that respectively correspond to the wild type
and to the F566A mutation of human AIF562–571 sequence (see
Table 2 for details). As shown in figure 1, pull down assays indicated
that DPT-AIF1 co-precipitates with PP1c from HeLa cell extracts.
In contrast, PP1c is not detected in pull down experiments with
control beads or mutant peptide DPT-AIF2. Similar results are also
found with Jurkat cells (data not shown). These data demonstrate
that the single exchange of the F566A residue in the R/Kx(0.1)V/
IxFxxR/KxR/K motif of the AIF562–571 sequence is sufficient to
specifically prevent PP1c binding.
AIF562–571 is a new cell penetrating and cell death
domain
We previously reported that intracellular delivery of a functional
FxxR/KxR/K PP1c-interacting motif, deduced from the se-
quence of the pro-apoptotic Bad protein, triggered cell death in
human HeLa and Jurkat cells [7]. Given that AIF562–571 shares a
similar FxxR/KxR/K PP1c docking motif, we hypothesized that
it might constitute a cell penetrating and cell death sequence. To
test this hypothesis, an investigation was conducted into the ability
of biotinylated DPT-AIF1 and DPT-AIF2 peptides to penetrate
and deliver a protein marker (Streptavidin-HRP) into HeLa cells.
As shown in figure 2A, both DPT-AIF1 and DPT-AIF2 were
localized into the cytoplasm of HeLa cells. However only DPT-
AIF1, not DPT-AIF2, was able to internalize Streptavidin-HRP
conjugated molecules even more efficiently than the well
characterized positive control TAT peptide (Figure 2B). We also
found that DPT-AIF1, but not mutant DPT-AIF2, was able to
induce loss of viability in adherent HeLa cells (Fig. 3A). Similar
effects were observed in six other adherent cells (Fig. 3B). More
importantly, TUNEL assay showed that DPT-AIF1, but not DPT-
AIF2, induced apoptosis in adherent HeLa cells (Fig. 3C).
Experiments using Annexin V or DiOC assays indicated that
DPT-AIF1, but not DPT-AIF2, induced apoptosis in non-adherent
Jurkat cells.
Together, these results demonstrate that AIF562–571 contains a
functional R/Kx (0,1)V/IxFxxR/KxR/K motif that possesses cell
penetrating and cell death properties.
The 564–VIFYLRDK–571 sequence of AIF containing the
FxxR/KxR/K motif is sufficient for PP1c binding
As shown in Fig. 4A, a structural analysis of AIF based on its
published crystal structure [10] suggests that the sequence
corresponding to residues 562–571 in human AIF adopts a b
Figure 4. Structural model and biochemical analyses of PP1c
interacting sequences in DPT-AIF deletion peptides. (A)
Localization of the PP1c binding site in a ribbon representation
deduced from the AIF crystal structure obtained from PDB. The PP1c
binding site (residues 562–571 in blue) is located in an anti-parallel b-
strand. The critical F566 residue mutated in the DPT-AIF2 sequence is
shown in yellow. (B) DPT-AIF3 sequence and DPT-AIF4 peptides
containing 8 accessible residues of AIF564–571. (C) Pull down experiments
to analyze co-precipitation of DPT-AIF3 and DPT-AIF4 peptides with
PP1c for HeLa cell extracts.
doi:10.1371/journal.pone.0009981.g004
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be exposed, suggesting that the minimal 564–VIFYLRDK–571
sequence may be sufficient for PP1c interaction. To test this
hypothesis, we chemically synthesized two distinct wild type and
mutated DPT-AIF peptides sharing sequential N-terminal deletion
of the human AIF562–571 sequence (see Fig. 4B for sequence
details). As shown in Fig. 4C, pull down experiments showed that
DPT-AIF3, which corresponds to the 564–VIFYLRDK–571
sequence containing the FxxR/KxR/K motif, can efficiently
co-precipitate PP1c. In contrast, DPT-AIF4 containing the F566A
mutation in the DPT-AIF-2 sequence was unable to co-precipitate
PP1c.
Human APAF-1122–131 contains a combinatorial R/Kx(0,1)V/
IxxR/KxR/K PP1c-interacting motif. As illustrated in
figure 5A, the combinatorial PP1c docking motif deduced from
AIF562–571 is found in the sequence of several proteins involved in the
c o n t r o lo fc e l ls u r v i v a lp a t h w a y s . We therefore hypothesized that
APAF-1122–131, an APAF-1 domain containing the combinatorial
PP1c docking motif deduced from AIF-1562–571, can also bind PP1c.
Consistent with this hypothesis, a PP1c binding assay showed that
APAF-1122–131 can bind to PP1c in vitro (Fig. 5B). However, in
contrast to AIF562–571,A P A F - 1 122–131 is not a cell penetrating
sequence (data not shown).
Discussion
AIF562–571: a new PP1c interacting sequence with cell
penetrating and apoptotic properties
This work is based on our initial observation which suggested
that AIF562–571, the sequence located in the c-terminal portion of
AIF can bind to PP1c trough a potential PP1c consensus docking
motif defined by the 10 aa residues R/Kx(0.1)V/IxFxxR/KxR/K.
Remarkably, this sequence combines two distinct PP1c docking
motifs: 1) R/Kx(0,1)V/IxF, a well characterized universal conven-
Figure 5. In vitro molecular analysis of the PP1c docking motif in the APAF-1122–131 domain. (A) Proteins involved in the control of cell
survival pathways with a putative apoptotic signature that combines the two PP1c docking motifs (R/K)-x(0,1)-V/I-x-F-and F-x-x-R/K-x-R/K. (B)
Autoradiogram of the PP1 binding assay on cellulose-bound APAF-1 peptides. 7 overlapping dodecapeptides with a two-amino acid shift scanning
the sequence encompassing aa residues 119–141 of the APAF-1 sequence were synthesized on a cellulose membrane. The membrane was incubated
with PP1c holoenzyme and subsequently with anti-1c antibodies followed by peroxidase-labelled anti-mouse antibodies. The residues corresponding
to the PP1c consensus binding motif are shown in bold.
doi:10.1371/journal.pone.0009981.g005
PP1-Dependent Apoptotic Motif
PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e9981tional consensus motif, and 2) FxxR/KxR/K, a motif that we
initially identified in Bcl-xL, Bcl-w and Bad proteins [6,7].
Interestingly, this second motif is also present in most known
PP1c binding proteins including inhibitor-2 [5,11].
It is well established that, in both motifs, the mutation of their
unique F residue, usually the F to A mutation, inhibits PP1c
binding. Consequently, pull down experiments with DPT-AIF2
and DPT-AIF3 peptides, respectively containing the F566A
mutation and the KV562-563 deletion in the AIF562–571 sequence,
indicate that the 564–VIFYLRDK–571 sequence containing the
FxxR/KxR/K motif is critically involved in PP1c-binding. The
PP1c binding site in the R/Kx(0.1)V/IxF motif has previously been
characterized. Structural studies based on the co-crystal analysis of
PP1c and a synthetic peptide containing a synthetic fragment of
the muscle GM protein indicated that this motif binds to an
hydrophobic channel in the c-terminal region of PP1c [12,13]. In
contrast, the PP1c binding site in the FxxR/KxR/K motif is still
unknown. Since both types of motif contain an F and an R/K
residue, it is unclear whether the two motifs bind to the same or to a
different site on PP1c. Future work based on co-crystal structure
studies with a synthetic peptide, containing the 564–VIFYLRDK–571
sequence and PP1c, will be required to determine the binding
sequence of a FxxR/KxR/K motif on PP1c. Furthermore,
mutagenesis and functional studies of PP1c mutated within the
binding sequence of this motif will be used to determine the
functional role of the FxxR/KxR/K-PP1c interaction on PP1
activity and on AIF mediated apoptosis.
Surprisingly, AIF562–571 also behaves as a new cell penetrating
sequence able to internalize HRP complex and induce apoptosis in
cultured cells. In addition, similarly to the regulation of PP1c
binding, the F566A mutation in DPT-AIF2 counteracts these
effects. A similar situation has previously been reported with a Bad
interacting FxxR/KxR/K motif coupled to inactive non trans-
ducing shuttle DPT-sh1 [7]. Together, these data suggest that
intracellular transduction is favored by the specific interaction with
PP1c. In addition, we confirm that PP1c targeting by a DPT-
interacting molecule containing PP1c-interacting FxxR/KxR/K
motif is sufficient to induce cell death.
R/K-x(0,1)V/IxFxxR/KxR/K: a PP1-dependent apoptotic
signature and new tool for drug design?
Interestingly, and similarly to AIF562–571, APAF-1122–131,a
sequence located downstream of the CARD domain of human
APAF-1 proteins, contains a PP1c consensus docking motif defined
by the 10 aa residues R/Kx(0,1)V/IxFxxR/KxR/K. APAF-1122–131
binds in vitro to PP1c. However, although it contains a motif similar
to AIF562–571, APAF-1122–131 is not a cell penetrating sequence. The
difference between AIF562–571 and APAF-1122–131 occurs in the non
conserved residues within their PP1c docking motif since P123,
V127 and D130 in APAF-1122–131 are respectively replaced by G, Y
and D in AIF562–571.
The authors of previous studies have already proposed that
short bioactive peptides containing phenylalanine, leucine, and
lysine residues could be used in antibacterial, antifungal, and
anticancer applications [14,15,16]. Other reports have document-
ed anti-tumor effects by cationic synthetic peptides. For example,
Araya et al., [17] characterized a 13-mer peptide containing the
KKYKAYFKLKCKK polycationic sequence derived from snake
venom that exerts anti-tumor effects. Interestingly, this peptide
contains a potential FxxR/KxR/K PP1-docking motif suggesting
that binding of this peptide to PP1c may be involved in the
apoptotic process.
In this context, the PP1-dependent apoptotic signature motif
deduced from the AIF562–571 sequence obviously represents a new
potential target for drug design. It is noteworthy, as illustrated in
Fig. 5A, that this new apoptotic motif is found in several proteins
involved in the control of cell survival pathways. Further work will
be required to determine the role of this PP1c-dependent
apoptotic signature in pathways controlled by these proteins,
including AIF and APAF-1 themselves.
In conclusion, our results support the concept of Drug
Phosphatase Technology as an original approach targeting PP1/
PP2A phosphatases to generate new specific and non toxic cancer
drugs. In this study our results established that the PP1 docking
motif R/Kx(0,1)V/IxFxxR/KxR/K deduced from the AIF562–571
sequence represents a potential PP1-dependent combinatorial
death motif. We have already characterized DPT-AIF1 as a new
cell penetrating pro-apoptotic peptide. Future work will be
necessary to determine the potential anti-tumor activity of this
molecule.
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